Jeff Tolin uses sophisticated techniques to ensure tax efficiency for his clients and allow them to reach their business objectives. Above all else, Jeff understands that tax planning and structuring must be consistent with client businesses and goals, so he focuses on finding practical, effective solutions that align with his clients' vision.
Cooley advised Rooam, a contactless payment platform that integrates directly into existing point of sale systems without adding extra hardware, on its agreement to be acquired by American Express (NYSE: AXP), a globally integrated payments company providing customers with access to products, insights and experiences that enrich lives and build business success.
Cooley advised Yardi Systems, a large software corporation with offices worldwide, in connection with WeWork’s emergence from Chapter 11 and completion of WeWork’s global operational and financial restructuring.
Cooley advised Nuvalence, a technology consultancy firm, on its acquisition by EY to accelerate the delivery of platform engineering, product development, and generative artificial intelligence platform-enabled services to organizations across industries and sectors.
Brii Biosciences Announces Agreements to Acquire VBI Vaccines’ IP Rights in BRII-179
February 14, 2024
Cooley advised Brii Biosciences on its agreements with VBI Vaccines (NASDAQ: VBIV) to ensure expansion and control of future clinical and commercial supplies of BRII-179, a late-stage clinical asset in Brii Bio’s hepatitis B virus functional cure portfolio. With operations in major biotechnology centers in the US and China, Brii Bio (HKSE: 2137) is a Hong Kong Stock Exchange-listed biotechnology company developing therapies to improve patient health and choice across diseases with high unmet needs.
COUR Pharmaceuticals Secures $105 Million Series A
January 30, 2024
Cooley advised COUR Pharmaceuticals, a clinical-stage biotechnology company focused on the development of first-in-class disease-modifying therapies designed to induce antigen-specific tolerance for immune-mediated diseases, on the close of its $105 million Series A financing.